Jane Street
RAPP icon

Jane Street’s Rapport Therapeutics RAPP Stock Holding History

Jane Street’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$450K Buy
13,400
+8,400
+168% +$363K ﹤0.01% 8259
2026
Q2 		$208K Buy
+5,000
New +$184K ﹤0.01% 10051
2025
Q4 		– Sell
-51,100
Closed -$1.52M – 12664
2025
Q3 		$1.52M Buy
+51,100
New +$912K ﹤0.01% 5449

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Jane Street's RAPP Position: Q3 2026 in Review

Jane Street increased its Rapport Therapeutics (RAPP) stake by 10% in Q3 2026, buying an estimated $252K and bringing the position to 61,533 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5094.

Jane Street first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.32M in Q2 2026. 114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Jane Street held 61,533 shares of Rapport Therapeutics worth $2.07M as of Q3 2026.
  • Jane Street bought 5,828 Rapport Therapeutics shares in Q3 2026, an estimated $252K.
  • Rapport Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #5094 holding.
  • Jane Street first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jane Street's Rapport Therapeutics position peaked at $2.32M in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.